Exencial Wealth Advisors LLC Makes New $593,000 Investment in McKesson Corporation $MCK

Exencial Wealth Advisors LLC acquired a new position in McKesson Corporation (NYSE:MCK) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 723 shares of the company’s stock, valued at approximately $593,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Obsidian Personal Planning Solutions LLC increased its stake in McKesson by 2.9% in the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock worth $346,000 after acquiring an additional 12 shares during the last quarter. IAM Advisory LLC boosted its holdings in shares of McKesson by 0.3% in the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after purchasing an additional 13 shares during the period. PDS Planning Inc boosted its holdings in shares of McKesson by 1.1% in the 3rd quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after purchasing an additional 13 shares during the period. Berkshire Asset Management LLC PA boosted its holdings in shares of McKesson by 4.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after purchasing an additional 13 shares during the period. Finally, Norden Group LLC boosted its holdings in shares of McKesson by 4.3% in the 4th quarter. Norden Group LLC now owns 317 shares of the company’s stock worth $260,000 after purchasing an additional 13 shares during the period. Institutional investors own 85.07% of the company’s stock.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson sold its stake in Medical?Surgical Solutions, a move that could unlock cash and simplify the company’s portfolio — potentially supporting buybacks or redeployment of capital. McKesson sells stake in Medical-Surgical Solutions
• Positive Sentiment: McKesson Canada secured national distribution for naturemary, expanding reach into thousands of pharmacies — a small but constructive revenue/market-access win in consumer and retail channels. naturemary Secures National Distribution with McKesson Canada, Unlocking Access to Thousands of Pharmacies
• Positive Sentiment: McKesson put a new $5.0 billion senior unsecured revolving credit facility in place, strengthening liquidity and debt flexibility ahead of potential strategic investments or cash-return programs. McKesson Secures New $5 Billion Revolving Credit Facility
• Neutral Sentiment: Analysts are re?weighing McKesson’s valuation relative to its biosimilars/co?manufacturing optionality; fair value estimates moved only marginally, but individual price targets diverge — highlights evolving thesis but no consensus catalyst yet. How The Narrative On McKesson (MCK) Is Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: Investor pieces pitching McKesson as a way to play GLP?1 channel growth highlight upside scenarios but are speculative and unlikely to move fundamentals immediately. GLP-1 trade? McKesson is your stock, this investor says
• Neutral Sentiment: Reports that lawmakers have been increasing holdings in McKesson attracted press attention — notable for optics but not a direct operational driver. Lawmakers increase stakes in McKesson, Boeing, Alphabet amid scrutiny
• Negative Sentiment: Market coverage noted McKesson fell more steeply than the broader market today, reflecting investor selling pressure and concerns over the stock’s premium to historical averages. McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Competitor coverage (William Blair initiating Cardinal Health at Outperform) highlights investor appetite for distributor exposure elsewhere, which could pressure McKesson’s multiple if flows shift to peers. William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder?

Insiders Place Their Bets

In related news, EVP Michele Lau sold 2,725 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the transaction, the executive vice president owned 3,247 shares in the company, valued at $3,214,530. The trade was a 45.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,592 shares of company stock worth $3,518,555 in the last 90 days. 0.08% of the stock is owned by insiders.

McKesson Stock Down 1.4%

MCK opened at $823.68 on Thursday. The business has a fifty day moving average of $897.30 and a 200 day moving average of $859.47. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00. The stock has a market cap of $100.89 billion, a P/E ratio of 23.69, a PEG ratio of 1.20 and a beta of 0.42.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the previous year, the business earned $8.03 EPS. McKesson’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities analysts anticipate that McKesson Corporation will post 39.02 EPS for the current fiscal year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s payout ratio is presently 9.43%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on MCK shares. Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. William Blair started coverage on McKesson in a report on Tuesday. They issued an “outperform” rating for the company. Mizuho lifted their target price on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. UBS Group dropped their target price on McKesson from $1,012.00 to $1,000.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, JPMorgan Chase & Co. lifted their target price on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $972.27.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.